Director, Analytical Development

The Role

In this role, you will lead the Innovative Technology and Methodology capability within Analytical Development and report to the Head of Analytical Development. You will set and execute the strategy for next-generation analytical methods and technologies, translating emerging scientific capabilities into robust, scalable, and sustainable solutions across the Quality Control network. Success in this role requires the ability to connect scientific innovation with product and control‑strategy needs, operational realities, regulatory expectations, and measurable business value.

You will partner closely with Analytical Sciences, Analytical Product Leads (APLs), Analytical Sciences & Technology (AST), Quality Control (QC), and other CMC functions to build an end‑to‑end pathway from technology identification and proof of concept through method development, transfer, implementation, and lifecycle adoption.

Here’s What You’ll Do

Lead the Innovative Technology and Methodology capability within Analytical Development, establishing the vision, scientific strategy, portfolio, and roadmap for next‑generation analytical methods and technologies across clinical and commercial products. Build and govern an end‑to‑end analytical innovation pipeline that identifies unmet analytical needs, evaluates emerging technologies, prioritizes opportunities, develops proof‑of‑concept solutions, and advances successful technologies through development, qualification or validation strategy, transfer, and implementation.

Partner closely with Analytical Sciences, APLs, AST, and QC to translate product knowledge, control‑strategy needs, method performance trends, investigations, and network pain points into prioritized innovation programs with clear analytical target profiles and intended‑use requirements. Drive development and modernization of analytical methodologies across relevant scientific domains, including separation sciences, molecular and sequencing technologies, biophysical and spectroscopic methods, bioassays, microbiology, advanced characterization, and other emerging analytical platforms appropriate to mRNA and advanced therapeutic modalities.

Lead method transformation across the QC network by enabling replacement, simplification, consolidation, and harmonization of legacy methods with more robust, higher‑throughput, automation‑ready, and scalable platform approaches where scientifically and regulatorily justified. Partner with AST, QC, ATO, Quality, Regulatory, Digital, and Automation teams to establish practical implementation pathways for innovative methods, including bridging, transfer, validation, change management, digital integration, training, and sustained method performance across internal and external testing sites.

Embed science‑and risk‑based analytical development principles consistent with evolving global expectations, including ICH Q14 and Q2(R2), to ensure new methodologies are fit for intended purpose, appropriately robust, lifecycle‑ready, and supported by a defensible regulatory strategy.

Establish a strong external innovation network across instrument and technology vendors, biotechnology companies, academic collaborators, consortia, and other external partners; actively scout emerging capabilities and determine where external innovation can accelerate Moderna analytical strategy. Advance automation‑, digital‑, and data‑enabled analytical methodologies in partnership with relevant functions, designing methods and workflows that reduce manual variability, improve data integrity and review efficiency, and enable scalable deployment across the analytical network.

Define clear success measures and business cases for the innovation portfolio, including improvements in method…